首頁 > 市場調查報告書 > 醫療設備

體外診斷生技設備

市場調查報告書

商品編碼

1863441

分子腫瘤診斷市場按產品類型、技術、檢測類型、應用、癌症類型、最終用戶和檢體類型分類－2025-2032年全球預測

Molecular Oncology Diagnostics Market by Product Type, Technology, Test Type, Application, Cancer Type, End User, Sample Type - Global Forecast 2025-2032

出版日期: 2025年09月30日 | 出版商:

360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄圖表

預計到 2032 年，分子腫瘤診斷市場規模將達到 247.9 億美元，複合年成長率為 12.17%。

關鍵市場統計數據
基準年 2024	98.8億美元
預計年份：2025年	111億美元
預測年份 2032	247.9億美元
複合年成長率 (%)	12.17%

分子腫瘤診斷的簡明策略框架：重點關注臨床整合挑戰和相關人員的創新優先事項

分子腫瘤診斷領域正經歷著一場策略重組，其驅動力來自科技的快速發展、臨床實踐的演變以及醫療保健系統需求的轉變。彌合基因組學見解與臨床應用之間的鴻溝是該領域的核心，它能夠實現更早期的檢測、更精準的治療選擇以及對疾病動態的持續監測。診斷創新不僅限於提高檢測靈敏度，還包括工作流程整合、數據解讀以及將分子特徵轉化為臨床醫生可以放心使用的治療方案。

如今，臨床醫生、實驗室主任和行業相關人員面臨雙重挑戰：既要檢驗複雜檢測方法的有效性，又要將其無縫整合到現有的診斷和治療流程中。檢測方法的推廣應用取決於其性能的可重複性、監管規定的清晰度以及在不同患者群體中展現出的效用。同時，支付方和醫療系統越來越重視臨床和經濟價值的證據，迫使診斷方法的研發人員設計研究方案和證據包，以直接滿足這些決策標準。

因此，分子腫瘤診斷領域的領導企業必須在創新與務實的商業化策略之間取得平衡。他們必須持續投資可靠的檢驗和臨床檢驗，同時建立清晰的臨床應用案例和數據基礎設施，以支持結果解讀和報告。在此環境下，高品質、及時洞察技術趨勢、臨床應用模式和相關人員的獎勵，對於制定投資、合作和市場准入決策至關重要。

技術融合、監管調整和商業性合作如何從根本上改變臨床應用和產品差異化的路徑

多項變革正在重塑分子腫瘤診斷在研究、臨床實踐和商業管道中的價值創造方式。首先，高通量定序技術與先進生物資訊學的融合提高了腫瘤譜分析的準確性，使臨床醫生能夠擺脫基於單一標誌物的決策模式，並利用複雜的基因組特徵來指導治療方案的選擇和監測。其次，微創檢測方法已從概念驗證階段發展到常規臨床應用階段，加速了疾病的長期監測，並有助於更早發現復發和抗藥性機制。

同時，監管機構和支付方正在提供更靈活的報銷途徑，並展現出在證據框架方面開展合作的意願，以支持創新的診斷方法。這有助於建構一種迭代式的證據建構策略，將真實世界數據與前瞻性檢驗結合，從而在證實效用後實現快速的臨床應用。此外，分子診斷在腫瘤治療中的應用也促進了檢測開發人員、診斷實驗室和治療藥物公司之間新的商業性合作，使診斷開發時間表與藥物開發和擴大策略保持一致。

總而言之，這些變化要求診斷服務提供者專注於可擴展的實驗室運作、可互通的數據平台以及能夠提供具有臨床意義且可重複結果的解讀演算法。策略差異化越來越依賴端到端解決方案，這些方案將強大的分析能力與簡化的報告和決策支援工具相結合，從而更好地服務臨床醫生。隨著該領域的不斷發展，那些既掌握了相關科學原理又掌握了臨床實施路徑的機構將獲得最大的長期價值。

2025年美國關稅調整將重塑採購、製造地和採購風險管理，營運和戰略應對措施亟待訂定。

美國近期採取的關稅措施以及2025年前的貿易政策調整，為支持分子腫瘤診斷的全球供應鏈帶來了顯著的摩擦。儀器製造、試劑製備和耗材生產的關鍵零件通常依賴國際採購，而關稅結構的變化不僅推高了進口材料的成本，也促使供應商重組。這迫使診斷設備製造商和實驗室重新評估供應商多樣性、庫存策略和合約條款，以保障利潤率並維持偵測能力。

為此，許多企業正在實現供應商多元化，探索本地製造夥伴關係關係，或啟動雙重採購策略，以降低單一來源採購風險。採購部門正日益將關稅波動納入總體擁有成本 (TCO) 的計算，更加重視端到端的韌性和前置作業時間的可視性。同時，製造商也在評估建立區域生產基地和選擇性地對高價值零件進行垂直整合的可行性，以降低貿易衝擊的影響。

政策驅動的變化也影響商業談判，買賣雙方需要重新協商價格和服務契約，以反映投入成本的波動。對於實驗室和醫療系統而言，當務之急是確保獲得檢驗的檢測套組，並確保檢測的連續性。對於研發人員和設備製造商而言，策略重點在於平衡成本控制與創新和品管的投資需求。最終，解決關稅相關的供應中斷問題，需要各方協調一致的營運措施，以及與臨床需求和監管預期相符的積極主動的籌資策略。

多維度細分（按產品、技術、測試、應用、癌症類型、最終用戶和檢體類型分類）將如何指導策略性產品設計和臨床應用路徑

細分市場分析表明，產品差異化日益取決於儀器、試劑套件、軟體和服務之間的相互作用。儀器構成實驗室工作流程的基礎；試劑套件確保檢測的特異性；軟體和服務則提供結果解讀的擴充性和監管可追溯性。技術選擇對臨床路徑產生深遠影響：螢光原位雜合反應(FISH) 和免疫組織化學 (IHC) 對於標靶應用至關重要；微陣列技術繼續用於特定的研究和轉換應用；即時PCR提供快速且精準的分析。次世代定序(NGS) 以其廣度和深度脫穎而出。在 NGS 中，標靶定序、全EXOME定序和全基因測序各自具有獨特的臨床和研究效用，而標靶定序本身又可細分為綜合定序和熱點特異性定序。每個定序平台都針對廣泛、可操作的變異發現或精簡、以臨床為導向的變異檢測進行了最佳化。

檢測類型的細分將影響服務設計和臨床價值提案。液態生物檢體可實現微創的縱向監測，多基因檢測支持對臨床相關路徑進行同步分析，而單基因檢測則提供目標明確、可操作的結果。同時，全外EXOME和全基因組方法可提供廣泛的、以發現為導向的分析，從而為複雜或難治性病例提供資訊。應用主導的策略應使伴隨診斷與治療路徑保持一致，優先考慮考慮人群健康影響的早期檢測方法，並透過預後評估和監測工具支援個人化醫療，同時滿足研究應用的需求。

在評估臨床相關性時，關注癌症類型仍然是一個重要的觀點。乳癌、大腸癌、白血病、肺癌和攝護腺癌各自具有獨特的生物標記譜和治療路徑，這會影響檢測方法的選擇和檢驗要求。最終用戶（診斷實驗室、醫院/診所、製藥/生物技術公司和研究機構）面臨不同的營運限制和採購動機，因此需要客製化的產品和服務模式。此外，檢體類型——血漿檢測、唾液/尿液檢查、組織檢測和全血分析——決定了分析前流程，並影響分析的敏感度和特異性。總而言之，這些細分維度要求我們制定一個連貫的策略，將產品設計、臨床效用和部署環境連結起來，以最大限度地提高臨床應用率和營運效率。

區域策略差異和執行重點會影響監管應對措施、商業化模式和跨國擴張。

美洲、歐洲、中東和非洲以及亞太地區的區域趨勢決定了不同的優先事項和營運需求，進而影響診斷開發商和實驗室的監管策略、夥伴關係模式和服務提供方式。在美洲，臨床和商業活動通常專注於將診斷整合到既定的腫瘤治療路徑中，並與要求提供明確臨床效用證據的支付方協商醫保覆蓋範圍。該地區對快速臨床檢驗和與治療研發緊密結合的重視，推動了診斷提供者和藥物開發商之間的合作模式。

在歐洲、中東和非洲地區，監管協調和多樣化的報銷環境迫使相關人員設計適應性強的證據生成策略，以滿足當地需求。在這些市場營運的機構優先考慮模組化資料包和集中式檢測服務，同時加強與當地臨床網路的合作，以檢驗在特定區域患者群體中的效用。在亞太地區，大型、高容量的醫療保健系統與快速發展的分子診斷能力並存，推動了對可擴展檢測平台、本地製造夥伴關係關係以及支持高通量工作流程的數位化報告系統的投資。

跨區域企業發展需要考慮不同的醫療融資模式、臨床醫生執業模式和實驗室基礎設施。成功的市場進入者將根據各區域的製度環境調整其監管和商業策略，儘早與當地臨床相關人員和支付方建立聯繫，並制定符合該區域診斷技術普及曲線和營運能力的打入市場策略。制定協調一致的區域策略，既要滿足本地執行需求，又要充分利用集中式資料洞察，這將是確保業務持續發展的關鍵。

競爭定位與夥伴關係策略：分子腫瘤學領域診斷創新者與檢驗實驗室的差異化策略

分子腫瘤診斷領域的競爭格局由成熟的儀器製造商、專業檢測開發人員、實驗室網路和新興的數位化解讀平台組成。主要企業憑藉檢驗的分析性能、可重複的臨床級檢測以及符合監管和實驗室認證標準的完善品管系統脫穎而出。與製藥開發商進行伴隨診斷合作仍然是實現臨床意義的主要途徑，這不僅使診斷公司走上治療創新之路，還能共同產生證據，從而支持同步臨床應用。

規模較小、反應更敏捷的公司通常憑藉一些利基創新技術展開競爭，例如高度最佳化的靶向測序panel、專有的檢體穩定化化學方法以及能夠提高變異分類準確性和速度的解讀演算法。這些公司通常會與大型實驗室合作或獲得其授權，以擴大業務範圍並加速臨床應用。同時，實驗室網路和參考檢測機構正透過投資先進的檢測整合、自動化和生物資訊技術來擴展其服務組合，為醫療系統和臨床試驗申辦者提供承包解決方案。

在競爭激烈的市場環境中，差異化越來越依賴端到端的能力，這種能力需要將卓越的分析能力與面向臨床醫生的報告、以支付方為導向的證據包以及營運擴充性結合。聯盟和策略夥伴關係仍然是成長策略的核心，使我們能夠將技術優勢與分銷管道、報銷專業知識和臨床倡導相結合，從而推動產品應用。

為產業領導者提供具有高影響力、可操作的策略舉措，以加速臨床應用、保障營運並增強其商業性價值提案。

產業領導者應優先考慮一系列可操作的措施，將策略意圖轉化為可衡量的營運成果。首先，投資可互通的數據平台和決策支援工具，以增強基因組分析結果的臨床效用，並減輕臨床醫生的認知負擔。這些平台應支援標準化報告，與電子健康記錄整合，並提供簡潔明了、可操作的解讀，供臨床醫生直接應用於治療決策。其次，制定模組化的證據策略，結合分析檢驗和真實世界數據，在滿足監管機構和支付方要求的同時，不斷改善臨床效用的論點。

第三，我們將透過供應商多元化和探索關鍵零件及試劑的區域性生產夥伴關係，增強供應鏈韌性，降低政策主導的成本波動風險。第四，我們將促進與治療藥物研發公司進行有針對性的合作，共同開發伴隨診斷，確保檢測設計與臨床試驗終點保持一致。第五，我們將建構滿足終端使用者需求的商業模式，提供靈活的實驗室解決方案，從集中式參考服務到分散式檢查模式，並輔以完善的品質保證和培訓計畫。最後，我們將從產品開發的早期階段就融入衛生經濟學和結果研究，清楚地向支付方和醫療服務提供者展示產品價值，從而加快報銷談判和臨床應用。

透過以全面的方式執行這些努力，各組織可以加快臨床應用，保護利潤，並在分子腫瘤診斷生態系統中實現永續的差異化。

採用透明嚴謹的調查方法，結合對關鍵相關利益者的訪談、對二手文獻的綜合分析以及基於情境的分析檢驗。

這些研究結果所依據的調查方法結合了證據綜合、相關利益者參與和嚴格的分析檢驗，以確保其相關性和可信度。主要研究包括對臨床腫瘤學家、實驗室主任、診斷開發人員、採購人員和監管顧問進行結構化訪談，以收集有關臨床工作流程、檢驗要求和採購促進因素的第一手資料。次要分析整合了同行評審的科學文獻、臨床指南更新、監管出版刊物和營運案例研究，以闡明主要研究結果的背景並識別新興技術趨勢。

我們的分析方法檢驗於將定性資訊與已記錄的臨床路徑和監管指南進行交叉驗證，以降低病例偏差的風險。我們優先考慮假設的透明度和資訊來源的可追溯性，並運用情境推理檢驗政策變革和技術進步對實施時間表和相關人員的獎勵。我們盡可能地透過明確定義檢測性能特徵的評估標準、臨床效用聲明所需的證據等級以及實驗室整合的運作前提條件，來確保調查方法的嚴謹性。

這種系統化的方法能夠提供基於臨床病理實際應用的洞見，並充分考慮實驗室和醫療保健系統的運作限制。它透過將技術性能屬性與臨床工作流程和報銷趨勢聯繫起來，為決策提供支持，使相關人員能夠制定符合實際需求的循證策略和實施計劃。

整合策略重點，將分析嚴謹性、臨床完整性和營運韌性相結合，以最大限度地提高臨床和商業性影響力。

總之，分子腫瘤診斷處於技術可行性和臨床需求的交會點。要實現有意義的影響，需要的不僅僅是檢測技術的漸進式改進；它需要整合解決方案，將分析能力與臨床醫生的工作流程、循證策略、供應鏈韌性以及支付方的期望相協調。那些能夠促進互通數據平台、模組化證據生成以及與治療藥物研發者建立策略夥伴關係的機構，將更有能力將基因組學見解轉化為常規臨床決策。

營運韌性和市場反應能力同樣至關重要，尤其是在政策主導的成本調整和供應鏈壓力可能影響檢測連續性和定價的環境下。建構符合終端用戶實際情況的商業模式、投資於衛生經濟學證據以及優先考慮不同患者群體的臨床效用，這些都是能夠加速產品普及並維持長期價值的切實可行的步驟。最終，能夠在臨床醫生工作流程中提供清晰、可操作且可重複結果的診斷服務提供者將產生最大的臨床和商業性影響，從而提升癌症治療水平並改善患者預後。

整合人工智慧驅動的生物資訊平台，用於複雜腫瘤分析和標靶治療選擇
新興的基於 CRISPR 的液態生物檢體診斷技術可用於即時監測腫瘤學中的微量殘存疾病
擴展多體學檢測，整合基因組學、轉錄組學和蛋白質組學，用於個人化癌症診斷
在臨床實踐中，針對可操作癌症生物標記的次世代定序panel的應用日益廣泛。
開發數位病理學和人工智慧影像分析工具，以實現更準確的分子腫瘤診斷

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依產品類型分類的分子腫瘤診斷市場

裝置
試劑和套件
軟體和服務

9. 依技術分類的分子腫瘤診斷市場

螢光原位雜合反應
免疫組織化學
微陣列
次世代定序
- 標靶定序
  - 綜合小組
  - 熱點面板
- 全外EXOME定序
- 全基因測序
即時PCR

第10章依檢測類型分類的分子腫瘤診斷市場

液態生物檢體
多基因檢測
單基因檢測
全外EXOME定序
全基因組定序

第11章依應用分類的分子腫瘤診斷市場

伴隨診斷
早期檢測
個人化醫療
預後和監測
研究用途

第12章依癌症類型分類的分子腫瘤診斷市場

乳癌
大腸直腸癌
白血病
肺癌
攝護腺癌

第13章依最終用戶分類的分子腫瘤診斷市場

診斷實驗室
醫院和診所
製藥和生物技術公司
研究所

第14章依樣本類型分類的分子腫瘤檢體市場

基於等離子體
唾液/尿液
組織
全血

第15章各地區分子腫瘤診斷市場

美洲
- 北美洲
- 拉丁美洲
歐洲、中東和非洲
- 歐洲
- 中東
- 非洲
亞太地區

第16章分子腫瘤診斷市場（依組別分類）

ASEAN
GCC
EU
BRICS
G7
NATO

第17章各國分子腫瘤診斷市場

美國
加拿大
墨西哥
巴西
英國
德國
法國
俄羅斯
義大利
西班牙
中國
印度
日本
澳洲
韓國

第18章競爭格局

2024年市佔率分析
FPNV定位矩陣，2024
競爭分析
- F. Hoffmann-La Roche Ltd
- Thermo Fisher Scientific Inc.
- Illumina Inc.
- QIAGEN NV
- Bio-Rad Laboratories, Inc.
- Agilent Technologies, Inc.
- Danaher Corporation
- Hologic, Inc.
- Exact Sciences Corporation
- Guardant Health, Inc.

簡介目錄圖表

Product Code: MRR-5C6F41F5AFE6

The Molecular Oncology Diagnostics Market is projected to grow by USD 24.79 billion at a CAGR of 12.17% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 9.88 billion
Estimated Year [2025]	USD 11.10 billion
Forecast Year [2032]	USD 24.79 billion
CAGR (%)	12.17%

A concise strategic framing of the molecular oncology diagnostics domain highlighting clinical integration challenges and innovation priorities for stakeholders

The molecular oncology diagnostics landscape is undergoing a period of strategic realignment driven by rapid technological maturation, evolving clinical practice, and shifting health system imperatives. At its core, the field seeks to close gaps between genomic insight and clinical actionability, enabling earlier detection, more precise therapeutic selection, and continuous monitoring of disease dynamics. Diagnostic innovation is not limited to assay sensitivity; it spans workflow integration, data interpretation, and the translation of molecular signatures into treatment pathways that clinicians can deploy with confidence.

Clinicians, laboratory leaders, and industry stakeholders now face the dual challenge of validating complex assays while ensuring they integrate seamlessly into existing diagnostic and treatment workflows. Adoption depends on reproducible performance, regulatory clarity, and demonstrable utility across diverse patient populations. Meanwhile, payers and health systems increasingly demand evidence of clinical and economic value, prompting diagnostic developers to design studies and evidence packages that respond directly to these decision criteria.

As a result, leaders in molecular oncology diagnostics must balance innovation with pragmatic commercialization strategies. They must invest in robust analytical validation and clinical validation efforts, while also developing clear clinical use cases and data infrastructures that support interpretation and reporting. In this environment, high-quality, timely intelligence about technological trends, clinical adoption patterns, and stakeholder incentives becomes essential for shaping investment, collaboration, and market entry decisions.

How technological convergence, regulatory adaptation, and commercial alliances are fundamentally altering pathways for clinical adoption and product differentiation

Several transformative shifts are reshaping how molecular oncology diagnostics deliver value across research, clinical practice, and commercial channels. First, the convergence of high-throughput sequencing capabilities with advanced bioinformatics has expanded the granularity of tumor profiling, enabling clinicians to move beyond single-marker decisions toward composite genomic signatures that inform therapy selection and monitoring. Second, minimally invasive testing modalities have advanced from proof-of-concept to routine clinical utility, accelerating longitudinal disease monitoring and enabling earlier detection of relapse or resistance mechanisms.

Concurrently, regulatory and reimbursement pathways have become more dynamic, with agencies and payers signaling willingness to engage on evidence frameworks that accommodate innovative diagnostic modalities. This has encouraged more iterative evidence generation strategies that pair real-world data with prospective validation, fostering faster clinical adoption when utility is demonstrable. At the same time, integration of molecular diagnostics into oncology care is catalyzing new commercial partnerships between assay developers, diagnostics laboratories, and therapeutic companies, aligning diagnostic development timelines with drug development and label expansion strategies.

These shifts collectively demand that diagnostic providers focus on scalable laboratory operations, interoperable data platforms, and interpretive algorithms that deliver clinically meaningful, reproducible outputs. Strategic differentiation increasingly rests on end-to-end solutions that combine robust analytic performance with streamlined clinician-facing reports and decision-support tools. As the field evolves, organizations that master both the science and the operational pathways to clinical implementation will capture the greatest long-term value.

Operational and strategic responses to United States tariff adjustments in 2025 that are reshaping sourcing, manufacturing footprints, and procurement risk management

Recent tariff actions and trade policy adjustments in the United States for 2025 have introduced measurable friction into global supply chains that support molecular oncology diagnostics. Components critical to instrument manufacture, reagent formulation, and consumable production are often sourced internationally, and changes in tariff structures raise the cost of imported inputs while incentivizing supplier reconfiguration. This dynamic has prompted diagnostic manufacturers and laboratory operators to reassess supplier diversity, inventory strategies, and contract terms to protect margins and maintain uninterrupted testing capacity.

In response, many organizations have diversified their supplier base, sought local production partnerships, or initiated dual-sourcing strategies to reduce exposure to single-point supply risks. Procurement teams increasingly factor tariff volatility into total cost of ownership calculations, emphasizing end-to-end resilience and lead-time visibility. At the same time, manufacturers are evaluating the feasibility of regionalized manufacturing footprints and selective vertical integration for high-value components to mitigate exposure to trade-related shocks.

The policy-induced changes also influence commercial negotiations, with buyers and vendors renegotiating pricing and service commitments to reflect evolving input costs. For laboratories and health systems, the immediate priority is maintaining access to validated assays and preserving test continuity. For developers and instrument manufacturers, the strategic focus remains on balancing cost containment with the imperative to invest in innovation and quality control. Ultimately, resolving tariff-related disruption requires coordinated operational adjustments and forward-looking sourcing strategies that align with clinical demand and regulatory expectations.

How multi-dimensional segmentation across product, technology, test, application, cancer type, end user, and sample type determines strategic product design and clinical deployment pathways

Segmentation insight reveals that product differentiation is increasingly defined by the interplay between instruments, reagents and kits, and software and services, where instruments anchor laboratory workflows, reagents and kits enable assay specificity, and software and services deliver interpretive scale and regulatory traceability. Technology choices exert a profound influence on clinical pathways: fluorescence in situ hybridization and immunohistochemistry remain essential for targeted applications, microarray continues to serve select research and translational use cases, and real-time PCR provides rapid, focused analyses. Next generation sequencing stands out for breadth and depth; within NGS, targeted sequencing, whole exome sequencing, and whole genome sequencing offer distinct clinical and research utilities, and targeted sequencing itself differentiates into comprehensive panels and hotspot-focused panels, each optimized for either broad actionable variant discovery or streamlined, clinically focused mutation detection.

Test type segmentation shapes service design and clinical value propositions. Liquid biopsy enables minimally invasive longitudinal monitoring, multi-gene panel testing supports simultaneous interrogation of clinically relevant pathways, single gene testing delivers focused actionable results, and whole exome and whole genome approaches provide discovery-oriented breadth that can inform complex or refractory cases. Application-driven strategies must align companion diagnostics with therapeutic pathways, prioritize early detection modalities for population health impacts, and support personalized medicine through prognosis and monitoring tools while addressing research use needs.

Cancer type focus remains a critical lens for clinical relevance, with breast, colorectal, leukemia, lung, and prostate cancer each presenting distinct biomarker landscapes and care pathways that influence assay selection and validation requirements. End users - diagnostic laboratories, hospitals and clinics, pharmaceutical and biotech companies, and research institutes - have divergent operational constraints and purchasing drivers, which necessitates tailored product and service models. Finally, sample type considerations, spanning plasma-based assays, saliva and urine modalities, tissue-based testing, and whole blood analyses, determine pre-analytical workflows and influence analytic sensitivity and specificity. Taken together, these segmentation dimensions require cohesive strategies that link product design, clinical utility, and deployment environments to maximize clinical adoption and operational efficiency.

Regional strategic distinctions and execution priorities that influence regulatory engagement, commercialization models, and cross-border operational scaling

Regional dynamics reveal differentiated priorities and operational imperatives across the Americas, Europe, Middle East & Africa, and Asia-Pacific, shaping how diagnostics developers and laboratories approach regulatory strategy, partnership models, and service delivery. In the Americas, clinical and commercial activities often center on integrating diagnostics into established oncology care pathways and negotiating coverage with payers that demand clear evidence of clinical utility. This region emphasizes rapid clinical validation and close alignment with therapeutic development, driving collaborative models between diagnostics providers and pharmaceutical developers.

In Europe, the Middle East & Africa, regulatory harmonization and variable reimbursement landscapes prompt stakeholders to design adaptable evidence generation strategies that can address diverse national requirements. Organizations operating across these markets prioritize modular data packages and centralized laboratory services while also engaging local clinical networks to validate utility in region-specific patient populations. The Asia-Pacific region features a mix of large, high-volume healthcare systems and rapidly developing molecular capabilities, encouraging investments in scalable testing platforms, local manufacturing partnerships, and digital reporting systems that support high-throughput workflows.

Transitioning across regions requires sensitivity to differing healthcare financing models, clinician practice patterns, and laboratory infrastructure. Successful market entrants adapt regulatory and commercial approaches to each region's institutional landscape, engage early with local clinical and payer stakeholders, and tailor go-to-market strategies that reflect regional diagnostic adoption curves and operational capacity. Coordinated regional strategies that leverage centralized data insights while accommodating local execution imperatives will be critical for sustained impact.

Competitive positioning and partnership strategies that enable diagnostic innovators and laboratories to differentiate in a crowded molecular oncology landscape

Competitive dynamics in molecular oncology diagnostics are shaped by a mix of established instrument providers, specialized assay developers, laboratory networks, and emerging digital interpretation platforms. Leading players distinguish themselves through validated analytical performance, reproducible clinical-grade assays, and robust quality management systems that satisfy regulatory bodies and laboratory accreditation standards. Collaboration with pharmaceutical developers on companion diagnostics continues to be a primary route to clinical relevance, positioning diagnostic companies alongside therapeutic innovation pathways and enabling joint evidence generation that supports simultaneous clinical adoption.

Smaller, agile firms frequently compete on niche innovations - for example, highly optimized targeted sequencing panels, proprietary sample stabilization chemistries, or interpretive algorithms that improve variant classification and reduce turnaround time. These firms often partner with larger laboratories or engage in licensing deals to scale reach and accelerate clinical deployment. At the same time, laboratory networks and reference testing providers expand their service portfolios by integrating advanced assays and investing in automation and bioinformatics to offer turn-key solutions to health systems and clinical trial sponsors.

Across the competitive landscape, differentiation increasingly relies on end-to-end capabilities that combine analytical excellence with clinician-facing reporting, payer-aligned evidence packages, and operational scalability. Alliances and strategic partnerships remain central to growth strategies, enabling companies to pair technical strengths with distribution channels, reimbursement expertise, and clinical advocacy that drive adoption.

High-impact and implementable strategic actions for industry leaders to accelerate clinical adoption, safeguard operations, and strengthen commercial value propositions

Industry leaders should prioritize a set of actionable moves that translate strategic intent into measurable operational outcomes. First, invest in interoperable data platforms and decision-support tools that enhance the clinical utility of genomic findings and reduce clinician cognitive load. These platforms should support standardized reporting, integrate with electronic health records, and provide concise, actionable interpretations that clinicians can apply directly to treatment decisions. Second, develop modular evidence strategies that combine analytical validation with real-world performance data to satisfy both regulatory requirements and payer demands while enabling iterative refinement of clinical utility claims.

Third, strengthen supply chain resilience by diversifying suppliers and exploring regional manufacturing partnerships for critical components and reagents, thereby reducing exposure to policy-driven cost disruptions. Fourth, pursue targeted partnerships with therapeutic developers to co-develop companion diagnostics, ensuring alignment between assay design and clinical trial endpoints. Fifth, tailor commercial models to end-user needs by offering flexible laboratory solutions, from centralized reference services to distributed testing models supported by robust quality assurance and training programs. Finally, embed health economics and outcomes research early in product development to articulate value to payers and providers, facilitating more rapid reimbursement discussions and clinical uptake.

By executing these initiatives in an integrated fashion, organizations can accelerate clinical adoption, protect margin, and create durable differentiation within the molecular oncology diagnostics ecosystem.

A transparent and rigorous research methodology combining primary stakeholder interviews, secondary literature synthesis, and scenario-based analytical validation

The research methodology underpinning these insights combines evidence synthesis, stakeholder engagement, and rigorous analytical vetting to ensure relevance and reliability. Primary engagement included structured interviews with clinical oncologists, laboratory directors, diagnostic developers, procurement leaders, and regulatory advisors to capture firsthand perspectives on clinical workflows, validation expectations, and purchasing drivers. Secondary analysis incorporated peer-reviewed scientific literature, clinical guideline updates, regulatory publications, and case studies of operational implementations to contextualize primary findings and identify emergent technological trends.

Analytic approaches emphasized cross-validation of qualitative inputs with documented clinical pathways and regulatory guidance to reduce the risk of anecdotal bias. The methodology prioritized transparency in assumptions and traceability of sources, and applied scenario-based reasoning to explore how policy shifts or technological advancements could alter implementation timelines and stakeholder incentives. Wherever possible, methodological rigor included explicit criteria for evaluating assay performance characteristics, evidence tiers required for clinical utility claims, and operational prerequisites for laboratory integration.

This structured approach yields insights that are rooted in practical clinicopathologic realities and are sensitive to the operational constraints of laboratories and health systems. It supports decision-making by linking technical performance attributes to clinical workflows and reimbursement dynamics, enabling stakeholders to design evidence strategies and implementation plans that align with real-world needs.

Synthesis of strategic priorities that connect analytic rigor, clinical integration, and operational resilience to maximize clinical and commercial impact

In conclusion, molecular oncology diagnostics sit at the intersection of technological possibility and clinical necessity. The path to meaningful impact demands more than incremental assay improvements; it requires integrated solutions that align analytic performance with clinician workflows, evidence strategies, supply chain resilience, and payer expectations. Organizations that embrace interoperable data platforms, modular evidence generation, and strategic partnerships with therapeutic developers will be best positioned to translate genomic insights into routine clinical decisions.

Operational resilience and market agility are equally essential, particularly in the face of policy-driven cost adjustments and supply chain pressures that can affect assay continuity and pricing dynamics. Tailoring commercial models to end-user realities, investing in health economic evidence, and prioritizing clinical utility in diverse patient populations are practical steps that will accelerate adoption and sustain long-term value. Ultimately, diagnostic providers that deliver clear, actionable, and reproducible results within clinician workflows will achieve the greatest clinical and commercial impact, strengthening oncology care and improving patient outcomes.

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Integration of AI-driven bioinformatics platforms for complex tumor profiling and targeted therapy selection
5.2. Emergence of CRISPR-based liquid biopsy diagnostics for real-time monitoring of minimal residual disease in oncology
5.3. Expansion of multi-omics assays integrating genomics, transcriptomics, and proteomics for personalized oncology diagnosis
5.4. Rising adoption of next-generation sequencing panels targeting actionable cancer biomarkers in clinical practice
5.5. Development of digital pathology and AI-powered image analysis tools for more accurate molecular oncology diagnostics

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Molecular Oncology Diagnostics Market, by Product Type

8.1. Instruments
8.2. Reagents & Kits
8.3. Software & Services

9. Molecular Oncology Diagnostics Market, by Technology

9.1. Fluorescence In Situ Hybridization
9.2. Immunohistochemistry
9.3. Microarray
9.4. Next Generation Sequencing
- 9.4.1. Targeted Sequencing
  - 9.4.1.1. Comprehensive Panel
  - 9.4.1.2. Hotspot Panel
- 9.4.2. Whole Exome Sequencing
- 9.4.3. Whole Genome Sequencing
9.5. Real Time PCR

10. Molecular Oncology Diagnostics Market, by Test Type

10.1. Liquid Biopsy
10.2. Multi Gene Panel Testing
10.3. Single Gene Testing
10.4. Whole Exome Sequencing
10.5. Whole Genome Sequencing

11. Molecular Oncology Diagnostics Market, by Application

11.1. Companion Diagnostics
11.2. Early Detection
11.3. Personalized Medicine
11.4. Prognosis & Monitoring
11.5. Research Use

12. Molecular Oncology Diagnostics Market, by Cancer Type

12.1. Breast Cancer
12.2. Colorectal Cancer
12.3. Leukemia
12.4. Lung Cancer
12.5. Prostate Cancer

13. Molecular Oncology Diagnostics Market, by End User

13.1. Diagnostic Laboratories
13.2. Hospitals & Clinics
13.3. Pharmaceutical & Biotech Companies
13.4. Research Institutes

14. Molecular Oncology Diagnostics Market, by Sample Type

14.1. Plasma Based
14.2. Saliva & Urine
14.3. Tissue Based
14.4. Whole Blood

15. Molecular Oncology Diagnostics Market, by Region

15.1. Americas
- 15.1.1. North America
- 15.1.2. Latin America
15.2. Europe, Middle East & Africa
- 15.2.1. Europe
- 15.2.2. Middle East
- 15.2.3. Africa
15.3. Asia-Pacific

16. Molecular Oncology Diagnostics Market, by Group

16.1. ASEAN
16.2. GCC
16.3. European Union
16.4. BRICS
16.5. G7
16.6. NATO

17. Molecular Oncology Diagnostics Market, by Country

17.1. United States
17.2. Canada
17.3. Mexico
17.4. Brazil
17.5. United Kingdom
17.6. Germany
17.7. France
17.8. Russia
17.9. Italy
17.10. Spain
17.11. China
17.12. India
17.13. Japan
17.14. Australia
17.15. South Korea

18. Competitive Landscape

18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
- 18.3.1. F. Hoffmann-La Roche Ltd
- 18.3.2. Thermo Fisher Scientific Inc.
- 18.3.3. Illumina Inc.
- 18.3.4. QIAGEN N.V.
- 18.3.5. Bio-Rad Laboratories, Inc.
- 18.3.6. Agilent Technologies, Inc.
- 18.3.7. Danaher Corporation
- 18.3.8. Hologic, Inc.
- 18.3.9. Exact Sciences Corporation
- 18.3.10. Guardant Health, Inc.

簡介目錄圖表

LIST OF FIGURES

FIGURE 1. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
FIGURE 3. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 4. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
FIGURE 5. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
FIGURE 7. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
FIGURE 9. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024 VS 2032 (%)
FIGURE 11. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
FIGURE 13. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
FIGURE 15. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 17. AMERICAS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 18. NORTH AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 19. LATIN AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 21. EUROPE MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 22. MIDDLE EAST MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 23. AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 24. ASIA-PACIFIC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 25. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 26. ASEAN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 27. GCC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 28. EUROPEAN UNION MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 29. BRICS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 30. G7 MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 31. NATO MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 32. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
FIGURE 33. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 34. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

TABLE 1. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, 2025-2032 (USD MILLION)
TABLE 5. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
TABLE 7. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
TABLE 9. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
TABLE 11. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 13. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2025-2032 (USD MILLION)
TABLE 15. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2025-2032 (USD MILLION)
TABLE 17. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 19. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2025-2032 (USD MILLION)
TABLE 21. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2025-2032 (USD MILLION)
TABLE 23. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 25. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
TABLE 27. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2025-2032 (USD MILLION)
TABLE 29. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY GROUP, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY GROUP, 2025-2032 (USD MILLION)
TABLE 31. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 33. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2025-2032 (USD MILLION)
TABLE 35. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY GROUP, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY GROUP, 2025-2032 (USD MILLION)
TABLE 37. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 39. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY REGION, 2025-2032 (USD MILLION)
TABLE 41. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY GROUP, 2025-2032 (USD MILLION)
TABLE 43. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 45. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
TABLE 47. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
TABLE 49. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
TABLE 51. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 53. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, 2025-2032 (USD MILLION)
TABLE 55. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
TABLE 57. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
TABLE 59. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 61. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COMPREHENSIVE PANEL, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COMPREHENSIVE PANEL, BY REGION, 2025-2032 (USD MILLION)
TABLE 63. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COMPREHENSIVE PANEL, BY GROUP, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COMPREHENSIVE PANEL, BY GROUP, 2025-2032 (USD MILLION)
TABLE 65. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COMPREHENSIVE PANEL, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COMPREHENSIVE PANEL, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 67. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY HOTSPOT PANEL, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY HOTSPOT PANEL, BY REGION, 2025-2032 (USD MILLION)
TABLE 69. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY HOTSPOT PANEL, BY GROUP, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY HOTSPOT PANEL, BY GROUP, 2025-2032 (USD MILLION)
TABLE 71. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY HOTSPOT PANEL, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY HOTSPOT PANEL, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 73. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
TABLE 75. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
TABLE 77. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 79. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
TABLE 81. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
TABLE 83. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 85. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY REGION, 2025-2032 (USD MILLION)
TABLE 87. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2025-2032 (USD MILLION)
TABLE 89. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 91. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
TABLE 93. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2025-2032 (USD MILLION)
TABLE 95. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY LIQUID BIOPSY, BY GROUP, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY LIQUID BIOPSY, BY GROUP, 2025-2032 (USD MILLION)
TABLE 97. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY LIQUID BIOPSY, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY LIQUID BIOPSY, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 99. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY MULTI GENE PANEL TESTING, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY MULTI GENE PANEL TESTING, BY REGION, 2025-2032 (USD MILLION)
TABLE 101. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY MULTI GENE PANEL TESTING, BY GROUP, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY MULTI GENE PANEL TESTING, BY GROUP, 2025-2032 (USD MILLION)
TABLE 103. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY MULTI GENE PANEL TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY MULTI GENE PANEL TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 105. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SINGLE GENE TESTING, BY REGION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SINGLE GENE TESTING, BY REGION, 2025-2032 (USD MILLION)
TABLE 107. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SINGLE GENE TESTING, BY GROUP, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SINGLE GENE TESTING, BY GROUP, 2025-2032 (USD MILLION)
TABLE 109. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SINGLE GENE TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SINGLE GENE TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 111. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
TABLE 113. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
TABLE 114. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
TABLE 115. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 116. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 117. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
TABLE 118. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
TABLE 119. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
TABLE 120. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
TABLE 121. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 122. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 123. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 124. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
TABLE 125. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 126. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
TABLE 127. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
TABLE 128. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
TABLE 129. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 130. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 131. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY EARLY DETECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 132. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY EARLY DETECTION, BY REGION, 2025-2032 (USD MILLION)
TABLE 133. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY EARLY DETECTION, BY GROUP, 2018-2024 (USD MILLION)
TABLE 134. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY EARLY DETECTION, BY GROUP, 2025-2032 (USD MILLION)
TABLE 135. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY EARLY DETECTION, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 136. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY EARLY DETECTION, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 137. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 138. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2025-2032 (USD MILLION)
TABLE 139. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PERSONALIZED MEDICINE, BY GROUP, 2018-2024 (USD MILLION)
TABLE 140. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PERSONALIZED MEDICINE, BY GROUP, 2025-2032 (USD MILLION)
TABLE 141. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PERSONALIZED MEDICINE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 142. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PERSONALIZED MEDICINE, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 143. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PROGNOSIS & MONITORING, BY REGION, 2018-2024 (USD MILLION)
TABLE 144. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PROGNOSIS & MONITORING, BY REGION, 2025-2032 (USD MILLION)
TABLE 145. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PROGNOSIS & MONITORING, BY GROUP, 2018-2024 (USD MILLION)
TABLE 146. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PROGNOSIS & MONITORING, BY GROUP, 2025-2032 (USD MILLION)
TABLE 147. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PROGNOSIS & MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 148. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PROGNOSIS & MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 149. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY RESEARCH USE, BY REGION, 2018-2024 (USD MILLION)
TABLE 150. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY RESEARCH USE, BY REGION, 2025-2032 (USD MILLION)
TABLE 151. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY RESEARCH USE, BY GROUP, 2018-2024 (USD MILLION)
TABLE 152. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY RESEARCH USE, BY GROUP, 2025-2032 (USD MILLION)
TABLE 153. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY RESEARCH USE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 154. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY RESEARCH USE, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 155. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 156. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
TABLE 157. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 158. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2032 (USD MILLION)
TABLE 159. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2024 (USD MILLION)
TABLE 160. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2025-2032 (USD MILLION)
TABLE 161. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 162. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 163. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 164. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2032 (USD MILLION)
TABLE 165. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2024 (USD MILLION)
TABLE 166. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2025-2032 (USD MILLION)
TABLE 167. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 168. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 169. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 170. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY LEUKEMIA, BY REGION, 2025-2032 (USD MILLION)
TABLE 171. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2024 (USD MILLION)
TABLE 172. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY LEUKEMIA, BY GROUP, 2025-2032 (USD MILLION)
TABLE 173. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 174. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 175. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 176. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
TABLE 177. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
TABLE 178. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
TABLE 179. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 180. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 181. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 182. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2025-2032 (USD MILLION)
TABLE 183. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2024 (USD MILLION)
TABLE 184. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2025-2032 (USD MILLION)
TABLE 185. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 186. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 187. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 188. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
TABLE 189. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 190. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
TABLE 191. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
TABLE 192. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
TABLE 193. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 194. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 195. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 196. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
TABLE 197. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
TABLE 198. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
TABLE 199. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 200. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 201. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 202. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY REGION, 2025-2032 (USD MILLION)
TABLE 203. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
TABLE 204. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
TABLE 205. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 206. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 207. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 208. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
TABLE 209. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
TABLE 210. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
TABLE 211. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 212. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 213. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
TABLE 214. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
TABLE 215. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PLASMA BASED, BY REGION, 2018-2024 (USD MILLION)
TABLE 216. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PLASMA BASED, BY REGION, 2025-2032 (USD MILLION)
TABLE 217. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PLASMA BASED, BY GROUP, 2018-2024 (USD MILLION)
TABLE 218. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PLASMA BASED, BY GROUP, 2025-2032 (USD MILLION)
TABLE 219. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PLASMA BASED, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 220. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PLASMA BASED, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 221. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SALIVA & URINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 222. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SALIVA & URINE, BY REGION, 2025-2032 (USD MILLION)
TABLE 223. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SALIVA & URINE, BY GROUP, 2018-2024 (USD MILLION)
TABLE 224. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SALIVA & URINE, BY GROUP, 2025-2032 (USD MILLION)
TABLE 225. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SALIVA & URINE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 226. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SALIVA & URINE, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 227. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TISSUE BASED, BY REGION, 2018-2024 (USD MILLION)
TABLE 228. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TISSUE BASED, BY REGION, 2025-2032 (USD MILLION)
TABLE 229. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TISSUE BASED, BY GROUP, 2018-2024 (USD MILLION)
TABLE 230. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TISSUE BASED, BY GROUP, 2025-2032 (USD MILLION)
TABLE 231. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TISSUE BASED, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 232. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TISSUE BASED, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 233. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2024 (USD MILLION)
TABLE 234. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2025-2032 (USD MILLION)
TABLE 235. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2024 (USD MILLION)
TABLE 236. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2025-2032 (USD MILLION)
TABLE 237. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 238. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 239. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 240. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
TABLE 241. AMERICAS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
TABLE 242. AMERICAS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
TABLE 243. AMERICAS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 244. AMERICAS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
TABLE 245. AMERICAS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 246. AMERICAS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
TABLE 247. AMERICAS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 248. AMERICAS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
TABLE 249. AMERICAS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, 2018-2024 (USD MILLION)
TABLE 250. AMERICAS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, 2025-2032 (USD MILLION)
TABLE 251. AMERICAS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 252. AMERICAS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
TABLE 253. AMERICAS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 254. AMERICAS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
TABLE 255. AMERICAS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 256. AMERICAS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
TABLE 257. AMERICAS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 258. AMERICAS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
TABLE 259. AMERICAS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
TABLE 260. AMERICAS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
TABLE 261. NORTH AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 262. NORTH AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 263. NORTH AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 264. NORTH AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
TABLE 265. NORTH AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 266. NORTH AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
TABLE 267. NORTH AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 268. NORTH AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
TABLE 269. NORTH AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, 2018-2024 (USD MILLION)
TABLE 270. NORTH AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, 2025-2032 (USD MILLION)
TABLE 271. NORTH AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 272. NORTH AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
TABLE 273. NORTH AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 274. NORTH AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
TABLE 275. NORTH AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
TABLE 276. NORTH AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
TABLE 277. NORTH AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 278. NORTH AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
TABLE 279. NORTH AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
TABLE 280. NORTH AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
TABLE 281. LATIN AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 282. LATIN AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
TABLE 283. LATIN AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT